FDA expands Adequan indications

被引：0
|
作者：
不详
机构：
来源：
LARGE ANIMAL PRACTICE | 1997年 / 18卷 / 01期
关键词：
D O I：
暂无
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
引用
收藏
页码：7 / 7
页数：1
相关论文
共 50 条
  • [41] The FDA's decisions regarding new indications for approved drugs - Where's the evidence?
    Winker, MA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (16): : 1342 - 1343
  • [42] FDA analysis of patient enrollment by region in clinical trials for approved oncological indications.
    Kanapuru, Bindu
    Singh, Harpreet
    Fashoyin-Aje, Lola A.
    Myers, Adrian
    Kim, Geoffrey
    Farrell, Ann
    Pazdur, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] MODELING THE ECONOMIC IMPACT OF INCORPORATING ABOBOTULINUMTOXINA INTO AN INSTITUTIONAL FORMULARY FOR FDA-APPROVED INDICATIONS
    Mittler, J.
    Danchenko, N.
    Bouchard, J.
    VALUE IN HEALTH, 2021, 24 : S165 - S165
  • [44] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [45] Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016
    Zettler, Marjorie
    Nabhan, Chadi
    JAMA ONCOLOGY, 2018, 4 (07) : 993 - 994
  • [46] Discrepancies in therapeutic indications for the same oncology drugs among FDA, EMA, and Brazilian agency
    Blatt, Camila Marchi
    Furlanetto Miranda, Mario Henrique
    Barreto, Rafael Balsini
    Uliana, Barbara Andressa
    Bodnar, Denize
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Response of a Collagenase-Induced Tendon Injury to Treatment with a Polysulphated Glycosaminoglycan (Adequan)
    Oryan, Ahmad
    Goodship, Allen E.
    Silver, Ian A.
    CONNECTIVE TISSUE RESEARCH, 2008, 49 (05) : 351 - 360
  • [48] PHYSICIAN KNOWLEDGE OF THE FDA-APPROVED INDICATIONS OF COMMONLY PRESCRIBED DRUGS: RESULTS OF A NATIONAL SURVEY
    Moloney, R. M.
    Chen, D.
    Matthew, W.
    Alexander, G. C.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 : 139 - 140
  • [49] THE VOICE OF THE REGULATOR: HOW FDA APPRAISES CLINICAL OUTCOME ASSESSMENTS IN SUPPLEMENTAL SUBMISSIONS FOR EXPANDED INDICATIONS
    Meyers, O.
    de la Motte, A.
    VALUE IN HEALTH, 2022, 25 (07) : S546 - S546
  • [50] PHYSICIAN KNOWLEDGE OF THE FDA-APPROVED INDICATIONS OF COMMONLY PRESCRIBED DRUGS: RESULTS OF A NATIONAL SURVEY
    Moloney, R.
    Chen, D.
    Wynia, M. K.
    Alexander, G. C.
    VALUE IN HEALTH, 2009, 12 (03) : A79 - A80
12345